Developmental changes in the effects of drugs acting at NMDA or non-NMDA receptors on synaptic transmission in the chick cochlear nucleus (nuc. magnocellularis)

Brain Res Dev Brain Res. 1992 Jun 19;67(2):145-52. doi: 10.1016/0165-3806(92)90215-i.


The developmental pharmacology of excitatory amino acid (EAA) receptors in the chick cochlear nucleus (nucleus magnocellularis, NM) was studied by means of bath application of drugs and recording of synaptically-evoked field potentials in brain slices taken from chicks aged embryonic day (E) 14 through hatching (E21). The abilities of various EAA agonists (N-methyl-D-aspartate [NMDA], kainic acid, and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA]) to suppress postsynaptic responses by depolarization block and of EAA antagonists ((3-[RS]-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid [CCP], dizocilpine [MK-801], 6-nitro-7-sulfamoyl-benzo(F)quinoxaline-2,3 dione [NBQX], 6-cyano-7-nitroquinoxaline-2,3-dione [CNQX] and 6,7-dinitroquinoxaline-2,3-dione [DNQX]) to suppress these responses directly were assessed quantitatively. The results support the existence of NMDA receptors in NM and suggest that the ability of these receptors to influence synaptically-evoked responses declines dramatically during the last week of embryonic life. The results similarly suggest that the non-NMDA receptors in NM undergo changes in density and/or function during a period of development when the cochlear nucleus is undergoing a variety of morphological and functional transformations.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 6-Cyano-7-nitroquinoxaline-2,3-dione
  • Animals
  • Anticonvulsants / pharmacology
  • Chick Embryo
  • Cochlear Nerve / drug effects
  • Cochlear Nerve / embryology
  • Cochlear Nerve / physiology*
  • Dizocilpine Maleate / pharmacology
  • Dose-Response Relationship, Drug
  • Electric Stimulation
  • Embryonic and Fetal Development
  • Evoked Potentials / drug effects
  • Ibotenic Acid / analogs & derivatives
  • Ibotenic Acid / pharmacology
  • N-Methylaspartate / pharmacology*
  • Piperazines / pharmacology
  • Quinolinic Acid
  • Quinolinic Acids / pharmacology
  • Quinoxalines / pharmacology
  • Receptors, N-Methyl-D-Aspartate / drug effects
  • Receptors, N-Methyl-D-Aspartate / physiology*
  • Receptors, Neurotransmitter / drug effects
  • Receptors, Neurotransmitter / physiology*
  • Synapses / drug effects
  • Synapses / physiology*
  • Synaptic Transmission / drug effects*
  • alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid


  • Anticonvulsants
  • Piperazines
  • Quinolinic Acids
  • Quinoxalines
  • Receptors, N-Methyl-D-Aspartate
  • Receptors, Neurotransmitter
  • 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
  • SDZ EAA 494
  • Ibotenic Acid
  • N-Methylaspartate
  • Dizocilpine Maleate
  • 6-Cyano-7-nitroquinoxaline-2,3-dione
  • alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
  • Quinolinic Acid